CANBERRA: A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
Study Details
Study Description
Brief Summary
The study's main purpose is to asses the safety, tolerability, and effect of oral administration of RG7774 on the severity of diabetic retinopathy (DR) in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) and good vision.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Placebo Comparator: Group A Participants will receive an oral dose of placebo matched to RG7774 once daily (QD) |
Drug: Placebo
Participants will receive oral placebo matched to RG7774
|
Experimental: Group B Participants will receive a low oral dose of RG7774 QD |
Drug: RG7774
Participants will receive oral RG7774
|
Experimental: Group C Participants will receive a high oral dose of RG7774 QD |
Drug: RG7774
Participants will receive oral RG7774
|
Outcome Measures
Primary Outcome Measures
- Proportion of Participants with >/= 2-Step Improvement in the Early Treatment Diabetic Retinopathy Study (ETDRS) DR Severity Scale (DRSS) from Baseline at Week 36 Measured in the Study Eye [Week 36]
- Percentage of Participants with Adverse Events (AEs) [From baseline up to 52 weeks]
Secondary Outcome Measures
- Percentage of Participants with Anterior Segment Neovascularization (ASNV), new Proliferative Diabetic Retinopathy (PDR), new Diabetic Macular Edema (DME), and Pre-Existing DME Requiring Intervention [From baseline up to 52 weeks]
- Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye [Baseline; Week 36]
Eligibility Criteria
Criteria
Inclusion Criteria
-
Able and willing to provide written informed consent and to comply with the study protocol according to International Conference of Harmonization (ICH) and local regulations
-
Male and female patients of at least 18 years of age
-
Treatment naïve with moderately severe to severe NPDR defined as ETDRS DRSS 47 or 53
-
Patients are eligible with and without DME in either eye
-
BCVA score at screening of at least 70 letters in study eyes without DME and at least 75 letters in case DME is present
-
Clear ocular media and adequate pupillary dilation to allow acquisition of good quality retinal images.
-
Diagnosis of diabetes mellitus (DM) type 1 or type 2
-
Hemoglobin A1c (HbA1c) </= 12%.
-
A female is eligible to participate if she is not pregnant, not breastfeeding
Exclusion Criteria
Ocular criteria for study eye:
-
Prior treatment for DR or other retinal diseases with any approved or investigational therapy, including but not limited to intravitreal steroids, intravitreal anti-VEGF, light therapy, periocular pharmacological intervention, and laser (e.g. focal, grid, micropulse, or pan-retinal)
-
Uncontrolled glaucoma
-
Any concurrent intraocular condition (e.g. retinal detachment, dense cataract, epiretinal membrane with traction, or vitreomacular traction, etc.) that in the opinion of the Investigator could reduce the potential for improvement, require medical surgical intervention or may confound the visual and functional assessment and interpretation of study results
Concurrent ocular conditions in either eye:
-
Any active ocular infection
-
Any active intraocular inflammation
General Criteria:
-
Previous systemic use of anti-VEGF drugs within 6 months prior to screening
-
Complications of diabetes such as end-stage renal disease or liver disease
-
Currently untreated diabetes mellitus or previously untreated patients who initiated oral or injectable anti-diabetic medication within 3 months prior to screening
-
Uncontrolled blood pressure ([BP] defined as systolic > 180mmHg and/or diastolic >100 mmHg while patient at rest)
-
History of concurrent cardio-vascular disease not considered well controlled by the Investigator
-
Any major illness or major surgical procedure within one month before screening
-
History of or currently active other diseases, metabolic dysfunction, physical examination finding, malignancies not considered cured, or clinical laboratory findings giving reasonable suspicion of a condition that contraindicated the use of the investigational medicinal drug or that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications in the opinion of the investigator
-
Known hypersensitivity to any of the excipients of the drug used, fluorescein dye or dilating eye drops
-
Use of systemic medications known to be toxic to the lens, retina or optic nerve (e.g., deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines and ethambutol) used during the 6-month period prior to screening or likely need to be used
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Arizona Retina and Vitreous Consultants | Phoenix | Arizona | United States | 85021 |
2 | Retina Associates Tucson | Tucson | Arizona | United States | 85710 |
3 | Win Retina | Arcadia | California | United States | 91006 |
4 | Global Research Management | Glendale | California | United States | 91204 |
5 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Torrance | California | United States | 90502 |
6 | Retina Consultants of Southern Colorado PC | Colorado Springs | Colorado | United States | 80909 |
7 | Retina Group of New England | Waterford | Connecticut | United States | 06385 |
8 | Rand Eye | Deerfield Beach | Florida | United States | 33064 |
9 | Florida Retina Consultants | Lakeland | Florida | United States | 33805 |
10 | Florida Eye Associates | Melbourne | Florida | United States | 32901 |
11 | Medeye Associates | Miami | Florida | United States | 33143 |
12 | Retina Specialty Institute | Pensacola | Florida | United States | 32503 |
13 | Retina Vitreous Assoc of FL | Saint Petersburg | Florida | United States | 33711 |
14 | Southeast Retina Center | Augusta | Georgia | United States | 30909 |
15 | Marietta Eye Clinic | Marietta | Georgia | United States | 30060 |
16 | Retina Associated Ltd | Elmhurst | Illinois | United States | 60126 |
17 | University Retina and Macula Associates, PC | Lemont | Illinois | United States | 60439 |
18 | Cumberland Valley Retina PC | Hagerstown | Maryland | United States | 21740 |
19 | University of Michigan, Kellogg Eye Center | Ann Arbor | Michigan | United States | 48105 |
20 | Deep Blue Retina PLLC | Southaven | Mississippi | United States | 38671 |
21 | Sierra Eye Associates | Reno | Nevada | United States | 89502 |
22 | Envision Ocular, LLC | Bloomfield | New Jersey | United States | 07003 |
23 | Eye Associates of New Mexico | Albuquerque | New Mexico | United States | 87109 |
24 | Ophthalmic Consultants of Long Island | Rockville Centre | New York | United States | 11570 |
25 | Charlotte Eye Ear Nose and Throat Associates | Charlotte | North Carolina | United States | 28210 |
26 | Meridian Clinical Research | Cincinnati | Ohio | United States | 45219 |
27 | Erie Retinal Surgery | Erie | Pennsylvania | United States | 16507 |
28 | Charleston Neuroscience Institute | Ladson | South Carolina | United States | 29456 |
29 | Southeastern Retina Associates Chattanooga | Chattanooga | Tennessee | United States | 37421 |
30 | Charles Retina Institute | Memphis | Tennessee | United States | 38119 |
31 | Retina Res Institute of Texas | Abilene | Texas | United States | 79606 |
32 | Austin Clinical Research LLC | Austin | Texas | United States | 78750 |
33 | Retina Consultants of Texas | Bellaire | Texas | United States | 77401 |
34 | San Antonio Eye Center | San Antonio | Texas | United States | 78215 |
35 | Retinal Consultants of Houston | The Woodlands | Texas | United States | 77384 |
36 | Strategic Clinical Research Group, LLC | Willow Park | Texas | United States | 76087 |
37 | Sydney Eye Hospital | Sydney | New South Wales | Australia | 2000 |
38 | Sydney Retina Clinic and Day Surgery | Sydney | New South Wales | Australia | 2000 |
39 | Centre For Eye Research Australia | East Melbourne | Victoria | Australia | 3002 |
40 | Retina Specialists Victoria | Rowville | Victoria | Australia | 3178 |
41 | Specjalistyczny Ośrodek Okulistyczny Oculomedica | Bydgoszcz | Poland | 85-870 | |
42 | Gabinet Okulistyczny Prof Edward Wylegala | Katowice | Poland | 40-594 | |
43 | Centrum Medyczne UNO-MED | Krakow | Poland | 31-070 | |
44 | Centrum Diagnostyki i Mikrochirurgii Oka LENS | Olsztyn | Poland | 10-424 | |
45 | LensClinic | Rybnik | Poland | 44-203 | |
46 | Centrum Medyczne Julianow; Zeglarska | Łódź | Poland | 91-321 | |
47 | Emanuelli Research and Development Center LLC | Arecibo | Puerto Rico | 00612 | |
48 | Fakultna nemocnica s poliklinikou F.D. Roosevelta | Banska Bystrica | Slovakia | 975 17 | |
49 | Klinika Oftalmológie LFUK a UNB | Bratislava | Slovakia | 826 06 | |
50 | Očná klinika UNB a SZU | Bratislava | Slovakia | 851 07 | |
51 | 3F s.r.o | Košice | Slovakia | 040 11 | |
52 | Fakultna nemocnica Trencin | Trencin | Slovakia | 911 71 | |
53 | Fakultna nemocnica s poliklinikou Zilina; Ocne oddelenie | Zilina | Slovakia | 012 07 | |
54 | Hospital Universitari de Bellvitge; Servicio de Oftalmologia | Hospitalet De Llobregat | Barcelona | Spain | 8907 |
55 | Hospital General de Catalunya | San Cugat Del Valles | Barcelona | Spain | 08195 |
56 | Hospital Universitario Puerta de Hierro | Majadahonda | Madrid | Spain | 28222 |
57 | Hospital Dos de Maig | Barcelona | Spain | 08025 | |
58 | Hospital Clinic I Provincial | Barcelona | Spain | 08036 | |
59 | Clinica Barraquer | Barcelona | Spain | 8021 | |
60 | Pio del Rio Hortega University Hospital | Valladolid | Spain | 47012 | |
61 | Miguel Servet University Hospital | Zaragoza | Spain | 50009 | |
62 | Royal Victoria Hospital; Outpatients Department | Belfast | United Kingdom | BT12 6BA | |
63 | Colchester General Hospital | Colchester, Essex | United Kingdom | CO4 5JL | |
64 | Royal Surrey County Hospital; Eye Clinic Research office | Guilford | United Kingdom | GU2 7XX | |
65 | Hull University Teaching Hospitals NHS Trust | Hull | United Kingdom | HU3 2JZ | |
66 | Royal Liverpool University Hospital | Liverpool | United Kingdom | L7 8XP | |
67 | Nottingham University Hospitals NHS Trust | Nottingham | United Kingdom | NG7 2UH | |
68 | Sunderland Eye Infirmary | Sunderland | United Kingdom | SR2 9HP |
Sponsors and Collaborators
- Hoffmann-La Roche
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BP41321
- 2019-002067-10